

## SUBJECT INDEX – Volume 8

*Critical Reviews™ in Oncogenesis*

Page Numbers for Issues:

**Issue 1**, 1–109; **Issues 2&3**, 111–291; **Issue 4**, 293–393

- AIDS vaccine efficacy, 273  
Alternative splicing, 29  
Angiography, 293  
Animal models, 273  
Antioxidant, 47  
Antisense, 93  
Autoimmunity, 381  
*bcr/abl*, 93, 343  
Benign, 293  
c-Crk, 329  
*c-kit*, 93  
*c-myb*, 93  
Cell cycle, 71  
Cell motility, 343  
Childhood cancer genetics, 1  
CML, 93  
Coactivators, 29  
Costimulation, 381  
CrkI, 329  
CrkII, 329  
CrkL, 329  
Cytokine, 143  
Development, 47  
Echocardiography, 293  
Energy expenditure, 219  
Exercise, 219  
Focal adhesion, 343  
Genistein, 47  
Gene therapy, 381  
Growth factors, 305  
Hematopoiesis, 93  
HIV-1 vaccine candidates, 273  
Human prostate epithelial cells, 305  
Immortalization, 305  
Immune therapy, 381  
Immunosurveillance, 111  
Integrin, 343  
Leukemia, 93  
Lifestyle, 219  
Malignant, 293  
Meta-analysis, 219  
Methylation, 29  
MHC molecules, 381  
Mutation, 29  
Negative regulation, 359  
Nephrogenesis, 1  
Non-human primates, 273  
Neoplastic transformation, 305  
Occupation, 219  
Oligodeoxynucleotide, 93  
Oncogene, 71, 329  
Oncogenesis, 189, 359  
p53, 71  
*p125<sup>FAK</sup>*, 343  
Paxillin, 343  
Phosphorylation, 29  
Phosphotyrosine-binding domains, 189  
Protein-tyrosine kinase, 189, 359  
Protooncogenes, 189  
Quercetin, 47  
Ras, 189  
*Ras* oncogene, 305  
Receptor, 143, 189, 359  
Recombinant BCG vectors, 273  
Recombinant HIV-1 gp120, 273  
Recombinant viral vectors, 273  
Rho, 343  
Ribozyme, 93  
Scaffold protein, 359  
SH2, 329  
SH3, 329  
Signal transduction, 71, 143  
*Src*, 343  
*Src*-homology domains, 189

- T-cell-mediated immunity, 111  
Tensin, 343  
Transcription, 29, 71  
Tumor antigen, 111, 381  
Tumor rejection, 111  
Tumor suppressors, 71  
Tumor suppressor genes, 305
- Type II estrogen binding sites, 47  
Tyrosine kinase, 71  
*v-Crk*, 329  
*vav*, 93  
Whole inactivated virus, 273  
WT1, 1, 71